SS-31: Side Effects

Safety Notice#

The safety profile of SS-31 (elamipretide) is primarily characterized through controlled clinical trials including the Phase 3 TAZPOWER trial in Barth syndrome, the Phase 2a EMBRACE STEMI trial, and Phase 2 studies in heart failure with reduced ejection fraction and primary mitochondrial myopathy. Additionally, open-label extension studies have provided longer-term safety data in patients with Barth syndrome treated for up to several years. The information below is derived from these clinical data sources.

Clinical Trial Safety Profile#

Overall Tolerability#

Across clinical trials, elamipretide has been generally well tolerated. In the TAZPOWER trial, which evaluated 40 mg daily subcutaneous injection in patients with Barth syndrome over two 12-week treatment periods, the safety profile was consistent with what had been observed in earlier phase trials. The most commonly reported treatment-emergent adverse events were injection site reactions and headache. No treatment-related serious adverse events leading to discontinuation were attributed to elamipretide in the pivotal trial.

In the open-label extension studies for Barth syndrome, where patients received subcutaneous elamipretide for extended periods, the long-term safety profile remained consistent with that observed during the randomized portion of the trial. The durability of the tolerability profile over months to years of treatment is an important finding, given that Barth syndrome treatment would be expected to require chronic administration.

Injection Site Reactions#

Injection site reactions are the most frequently reported adverse event associated with subcutaneous elamipretide administration. These reactions include localized redness, pain, swelling, induration, and pruritus at the site of injection. They are typically mild in severity and self-limiting, resolving within hours to days without specific intervention. Injection site reactions are common with many subcutaneous peptide therapies and are not unique to SS-31.

In clinical trials, injection site reactions were generally manageable with rotation of injection sites and did not lead to treatment discontinuation. The frequency and severity did not appear to increase with duration of treatment, suggesting that local sensitization is not a significant concern with chronic administration.

Intravenous Administration Safety#

In the EMBRACE STEMI trial and other studies employing intravenous elamipretide, the safety profile differed from subcutaneous studies in that injection site reactions were not applicable. Intravenous infusion was well tolerated in the acute cardiac care setting, with no infusion-related reactions reported as treatment-limiting. The single-dose IV paradigm used in the STEMI trial provided limited data on repeated IV administration.

Cardiovascular Safety#

Given that SS-31 targets cardiac mitochondria and has been evaluated in patients with cardiac conditions, cardiovascular safety monitoring has been an important component of clinical trials. No clinically significant changes in heart rate, blood pressure, or cardiac conduction parameters attributable to elamipretide have been reported across clinical trials. Electrocardiographic monitoring in trials has not identified QT prolongation or other arrhythmogenic signals.

This is particularly relevant in the Barth syndrome population, where patients have underlying cardiomyopathy. The absence of adverse cardiovascular effects in this vulnerable population provides reassurance, though the small sample sizes inherent to ultra-rare disease trials limit the power to detect infrequent adverse events.

Laboratory Parameters#

Across clinical trials, no consistent patterns of clinically significant laboratory abnormalities have been attributed to elamipretide treatment. Hepatic transaminases, renal function markers, hematologic parameters, and standard metabolic panels have not shown treatment-related changes requiring intervention or dose modification.

Contraindications#

Severe Cardiac Conduction Abnormalities#

While SS-31 has not demonstrated direct effects on cardiac conduction, patients with severe cardiac conduction abnormalities were generally excluded from clinical trials. Safety data in this population are therefore limited, and caution is warranted until specific studies address this group.

Pregnancy#

No reproductive toxicology data from human pregnancies are available for elamipretide. Animal reproductive studies have been conducted as part of the development program, but detailed results are not publicly available. As with most investigational agents, use during pregnancy should be avoided unless the potential benefit clearly justifies the potential risk to the fetus.

Drug Interactions#

Other Mitochondrial-Targeted Agents#

No formal drug-drug interaction studies with other mitochondrial-targeted compounds (such as MitoQ, CoQ10, or Idebenone) have been reported. Because SS-31 modulates mitochondrial bioenergetics through cardiolipin stabilization, concurrent use of other agents that alter mitochondrial function could theoretically produce additive or unpredictable effects on electron transport chain activity and ATP production. The clinical significance of any such interaction is unknown.

Cardiotoxic Drugs#

SS-31 has demonstrated cardioprotective effects in preclinical models. Concurrent use with known cardiotoxic agents (such as anthracycline chemotherapeutics or certain tyrosine kinase inhibitors) presents a theoretical interaction of clinical interest. SS-31 could potentially mitigate cardiotoxicity from such agents, but it could also mask early signs of cardiac injury. No clinical data addressing these potential interactions are available.

Metabolic Considerations#

SS-31 is metabolized through proteolytic degradation to peptide fragments and amino acids. It is not expected to interact with cytochrome P450 enzymes or other major drug-metabolizing enzyme systems, reducing the likelihood of pharmacokinetic drug-drug interactions. However, formal metabolic interaction studies confirming this expectation have not been published.

Long-Term Safety Considerations#

The open-label extension studies in Barth syndrome provide the most extended safety data for elamipretide, with some patients treated for multiple years. These data have not revealed new safety signals emerging with prolonged use. However, the small number of patients in these extension studies limits the ability to detect rare adverse effects.

The theoretical concern that sustained modulation of cardiolipin-cytochrome c interactions could have unintended consequences over decades of use has not been addressed by available data. Because SS-31 inhibits the peroxidase activity of the cardiolipin-cytochrome c complex that triggers apoptosis, long-term suppression of this pathway could theoretically affect the normal cellular quality control mechanisms that depend on mitochondria-mediated apoptosis. This remains a theoretical concern without supporting clinical evidence.

Evidence Gaps#

• Formal drug-drug interaction studies have not been published
• Safety in patients with severe hepatic or renal impairment has not been specifically evaluated
• Pediatric-specific safety data are limited to the small Barth syndrome population
• No human reproductive toxicology data are available
• Long-term safety beyond several years of use is not yet characterized
• Safety in combination with other mitochondrial-targeted therapies is unknown

Related Reading#

• SS-31 overview and research guide
• SS-31 dosing protocols
• SS-31 risks and legal status